Month: June 2021

IRVINE, Calif., June 22, 2021 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company focused on developing products to treat and transform the lives of patients suffering from venous diseases, today announced the appointment of Ms. Rebecca Chambers to its board of directors. Ms. Chambers also will serve as a member of the Audit Committee. Ms. Chambers, currently Chief Financial Officer of Outset Medical, Inc., brings more than a decade of healthcare leadership experience. Over the course of her career, Ms. Chambers has led numerous financial functions as well as served in leadership roles in investor relations for publicly traded companies in the healthcare space. “We are pleased to welcome Rebecca as a new independent director to our board. Her extensive healthcare leadership experience in high...

VANCOUVER, British Columbia, June 22, 2021 (GLOBE NEWSWIRE) — Rio2 Limited (“Rio2” or “the Company”) (TSXV: RIO; OTCQX: RIOFF; BVL: RIO) announces positive results obtained from the Run-of-Mine (“ROM”) heap leaching trial for its Fenix Gold Project in Chile. The ROM heap leaching trial was conducted by personnel of Fenix Gold Limitada, the Chilean subsidiary of Rio2 Limited, and overseen by HLC Ingeniería y Construcción, Rio2’s independent metallurgical consultants who were awarded the process plant / site infrastructure construction contract for the Fenix Gold Mine last year. Material for the trial heap was drilled and blasted from areas of the Fenix North, Fenix Central and Fenix South deposits and composited to make a 426 tonne representative sample. The trial was conducted at Rio2’s infrastructure site located approximately...

AUG-3387 Active Against All Variants Tested Including the UK (B.1.1.7), South African (B.1.351), Indian (B.1.617.1), and Brazil (P.1) Variants MENLO PARK, Calif. and AUSTIN, Texas, June 22, 2021 (GLOBE NEWSWIRE) — Augmenta Bioworks, a biotechnology company enabling breakthroughs in medicine through immune profiling, and TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that AUG-3387 has been selected as the first lead monoclonal antibody for clinical development against COVID-19 under their Joint Development and Collaboration Agreement. Targeting the SARS-Cov2 spike protein, AUG-3387 was isolated from an asymptomatic patient and then identified...

WALL, N.J., June 22, 2021 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions featuring Identity-Bound Biometrics, today introduced SSO ConciergeTM, the latest enhancement to their award-winning PortalGuard platform. SSO Concierge provides single sign-on (SSO) capabilities that eliminate the need for passwords to thick client applications that do not support federated identity management. With this product enhancement, BIO-key PortalGuard continues its technology leadership as a unified IAM platform that best supports the complexity of the modern enterprise with the widest range of SSO and multi-factor authentication (MFA) options. Despite the continuing migration to cloud services, many enterprises maintain complex environments, including thick...

Next-Generation, Cloud-Based Platform Empowers More Than 25% of Home Health Providers Nationwide with Greater Patient Data Accuracy and Administrative Efficiency Across All Payers BOWIE, Md., June 22, 2021 (GLOBE NEWSWIRE) — Inovalon (Nasdaq: INOV), a leading provider of cloud-based platforms empowering data-driven healthcare, and Homecare HomebaseSM, LLC (HCHB), the leading agency management and EMR software platform for the home health and hospice industry, today announced that HCHB would exclusively offer the EASE® All-Payer application to their customers, representing more than 25% of the nation’s home health providers, to deliver greater administrative efficiencies and increased accuracy of payment processes. Maintaining the highest of standards required to effectively manage data submissions and processes pertaining to delivery...

ROTTERDAM, The Netherlands (22 June 2021) – IMCD N.V. (hereafter “IMCD” or the “Company”) announces that all resolutions proposed to the shareholders at the Company’s Annual General Meeting (“AGM”) held today were adopted. This includes the adoption of the financial statements for the year 2020 and approval of the dividend proposal of EUR 1.02 per share in cash. The dividend calendar is as follows: Thursday 24 June 2021 – Ex-dividend date Friday 25 June 2021 – Record date Monday 28 June 2021 – Payment date Further resolutions included the reappointment of Deloitte Accountants B.V. as external auditor for the year 2021. The 2020 Remuneration Report received a positive advisory vote with over 94% of voted casted in favor of the report. Details of the Annual General Meeting, including the voting results, are available...

WASHINGTON, June 22, 2021 (GLOBE NEWSWIRE) — FTI Consulting, Inc. (NYSE: FCN) today announced that Senior Managing Director Pat Pericak was one of 30 individuals recognized in Global Investigations Review’s Top FCPA Practitioners survey, which spotlights the leading lawyers and forensic advisors in the Foreign Corrupt Practices Act (“FCPA”) space. Commenting on the recognition, Paul Ficca, Global Leader of the Forensic and Litigation Consulting segment at FTI Consulting, said, “Pat is an outstanding professional and leader who plays a critical role in helping law firms and their clients conduct complex anti-corruption and other investigations. This well-deserved recognition is a further testament to his strong expertise in the forensic and litigation consulting field.” Mr. Pericak has over 20 years of experience assisting law firms...

MONTREAL, June 22, 2021 (GLOBE NEWSWIRE) — Vision Marine Technologies, Inc. (Nasdaq: VMAR) (“Vision Marine” or the “Company”), a global leader in the electric recreational boating industry serving both OEMs and consumers, is pleased to announce its participation in five of the world’s top upcoming boat shows. Vision Marine will showcase its first fully electric E-Motion™ powertrain to OEMs and consumers at:Maine Boat & Home Show August 13-15, 2021Newport International Boat Show September 16-19, 2021IBEX Tampa Bay September 28-30, 2021Ft. Lauderdale International Boat Show October 27-31, 2021Mets Trade Amsterdam November 16-18, 2021“We are excited about our upcoming attendance at these shows, where Vision Marine will be able to showcase to OEMs and consumers the most powerful electric outboard powertrain system...

CALGARY, Alberta, June 22, 2021 (GLOBE NEWSWIRE) — Pulse Oil Corp., (“Pulse” or the “Company”) (TSXV: PUL) announced today that Pulse’s Bigoray 12-04 well has been producing for 7 days through to Pulse’s 100% owned, Bigoray production facility and has produced an average of approximately 120 barrels of oil per day during that time. Including this new production, Pulse has produced an average of approximately 330 BOE/D of oil and gas production over the past 7 days and Pulse’s team is working to reactivate more oil wells at Bigoray in the near future. Pulse CEO, Garth Johnson commented, “We are happy with the new production from our 12-04 oil well and at today’s oil prices, adding production is a positive step forward for Pulse. We were planning to reactivate a few more Bigoray wells in the winter but with commodity prices...

HIGH POINT, N.C. and WESTON, Fla., June 22, 2021 (GLOBE NEWSWIRE) — vTv Therapeutics Inc. (“vTv”, Nasdaq:VTVT) and Cantex Pharmaceuticals, Inc. (“Cantex”) today announced that they have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon, vTv’s novel antagonist of RAGE (the receptor for advanced glycation endproducts). Stephen Marcus, M.D., president and chief executive officer of Cantex, stated: “RAGE has been implicated in several serious cancer complications associated with increased mortality and decreased quality of life. Our team has deep expertise and a successful track record in transforming known drugs into innovative products with large clinical and commercial potential. As such, the opportunity to develop azeliragon, a phase 2-ready oral...